Dyax Corporation

The Cbr Institute for Biomedical Research, Inc.

Edward Hirsch Cohen

Robert Charles Ladner

Rene Hoet

Kristin L Rookey

Horacio Gabriel Nastri

Hendricus Renerus Jacobus Mattheus Hoogenboom

Timothy Alan Springer

Isaac J Rondon

Laetitia Devy

Motomu Shimaoka

David Buckler

Aaron Sato

Arthur Charles Ley

Hendricus R Hoogenboom

Hendricus RJM Hoogenboom

René Hoet

Methods useful in constructing libraries that collectively display and/or express members of diverse families of peptides, polypeptides or proteins and the libraries produced using those methods. Methods of screening those libraries and the peptides, polypeptides or proteins identified by such screens.

Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries

Methods useful in constructing libraries that collectively display members of diverse families of peptides, polypeptides or proteins and the libraries produced using those methods. Methods of screening those libraries and the peptides, polypeptides or proteins identified by such screens.

Methods of constructing libraries of genetic packages that collectively display the members of a diverse family of peptides, polypeptides or proteins

Methods useful in constructing libraries that collectively display and/or express members of diverse families of peptides, polypeptides or proteins and the libraries produced using those methods are disclose. Methods of screening those libraries and the peptides, polypeptides or proteins identified by such screens are also disclosed.

Proteins that bind to matrix metalloproteinase 9 and methods of using such proteins are described.

Metalloproteinase 9 binding proteins

A library containing a collection of genetic packages that display a member of a diverse family of peptides, polypeptides or proteins and that collectively display at least a portion of the family, the displayed peptides, polypeptides or proteins being encoded by DNA sequences containing sequences encoding a heavy chain CDR region is described.

The disclosure provides, inter alia, binding proteins (e.g., antibodies) that bind to an integrin in an activated conformation, e.g., activated LFA-1 ('aLFA-1 '), e.g., relative to a non-activated conformation of LFA-1. In one embodiment, the binding proteins inhibit at least one function of an aLFA-1, e.g., inhibit a binding interaction between aLFA-1 and a cognate ligand of aLFA-1, e.g., an ICAM protein. The binding proteins can be used to treat or prevent an inflammatory disorder or other disorder.

Conformation specific antibodies

The disclosure provides, inter alia, binding proteins (e.g., antibodies) that bind to an integrin in an activated conformation, e.g., activated LFA-1 ('aLFA-1'), e.g., relative to a non-activated conformation of LFA-1. In one embodiment, the binding proteins inhibit at least one function of an aLFA-1, e.g., inhibit a binding interaction between aLFA-1 and a cognate ligand of aLFA-1, e.g., an ICAM protein. The binding proteins can be used to treat or prevent an inflammatory disorder or other disorder.

Compositions comprising non-naturally occurring serum albumin binding moieties are described, together with methods of use thereof, e.g., for detecting or isolating serum albumin molecules in a solution, for blood circulation imaging, and for linking therapeutics or other molecules to albumin. Preferred serum albumin binding peptides having a high affinity for human serum albumin are particularly disclosed.

Growing community of inventors

Belmont, MA, United States of America

Edward Hirsch Cohen